Oxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020

Udgivet den 29-04-2020  |  kl. 13:15  |  

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the Company), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on Tuesday, May 5, 2020.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day.  The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 8473556, approximately 15 minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com.  The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company.  We bring energy and invention to a world in need of diagnostic truth.  Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world's largest cause of death from infectious disease.  The T-SPOT.TB test has been approved for sale in over 60 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company is headquartered near Oxford, U.K. and in Marlborough, MA.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media and Investor Inquiries:
Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
mtmclaughlin@oxfordimmunotec.com

\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Internationale avisuddrag med Tesla, GM og Daimler
Første stigning i to år
Internationale avisuddrag med Boeing, Facebook og Softbank
Pandora sprænger analytkernes forventninger - og opjusterer
USA godkender koppevaccine til folk i høj risiko for mpox
 

Seneste nyheder

06:32 USA/lukning: Endnu en rekorddag med Nvidia og Apple i front
06:30 Kalender med link - fredag den 8. november
19:19 KORR: Torsdagens aktier: Revanche til Trump-ramte aktier bidrog til et pænt plus i C25
17:49 Europa/aktier: Britisk telekoncern straffet for nedjustering i stigende marked
17:06 Torsdagens aktier: Ravanche til Trump-ramte aktier bidrog til et pænt plus i C25
17:02 Torsdagens aktier: Ravanche til Trump-ramte aktier bidrog til et pænt plus i C25
17:02 Torsdagens obligationer: Renteoptur gik i sig selv igen før rentemelding fra USA
16:24 Prisen på containerfragt stiger for anden uge i træk
16:13 Asetek styrtdykker på børsen ved udsigt til kapitaforhøjelse
15:41 Flere britiske rentenedsættelser i vente, mener Sydbank - men ro i december
15:39 USA/åbning: Fortsatte stigninger i mere afdæmpet marked før Fed-melding
14:28 USA/tendens: Aktiefesten efter Trumps sejr ses fortsætte forud for rentemelding
13:18 Bank of England sænker renten for anden gang i år
13:09 Europa/aktier: It og materialer fører an i europæisk aktieoptur
13:03 Bank of England sænker renten 25 basispoint
12:27 Obligationer/middag: Politisk kaos i Tyskland sender renterne opad
12:03 Alm. Brand Group vinder markedsandele i Privat - har sagt farvel til kunder i Erhverv
11:56 Aktier/middag: Regnskabstrekløver trækker C25 i vejret mens Novo tynger
10:56 Prisen på containerfragt stiger for anden uge i træk
10:40 Novo fortsætter ned - kommentarer om 2025 spøger